Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Femasys reported results for the quarter ended September 30, 2026, on November 13, 2026. Total sales fell 44.5% on the timing of international FemBloc orders, while U.S. sales rose slightly to $347,039. The company closed a $30 million private placement in mid-August to build out its U.S. commercial team for the FemaSeed fertility portfolio and to fund the FemBloc pivotal trial. It also reported FDA acceptance of a modular PMA approach for FemBloc and twelve actively enrolling FINALE trial sites. Net loss was $4.56 million and cash was about $23.9 million.
Company's press release (SEC filing): Femasys Inc ↗
Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.
IndustryCompany releaseIM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
IndustryCompany releaseHelus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IndustryCompany releaseIM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
IndustryCompany releaseDataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
IndustryCompany releaseXenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
IndustryCompany release